Cefpodoxime Proxetil Tablet 200 mg is indicated for the treatment of the following infections when caused by susceptible pathogens in adults:
Upper Respiratory Tract Infections: Acute bacterial sinusitis, tonsillitis.
Lower Respiratory Tract Infection: Acute exacerbation of chronic bronchitis, bacterial pneumonia—cefpodoxime might not be a suitable option depending on the pathogen involved.
Consideration should be given to the official guidance on the appropriate use of antibacterial agents.
Cefpodoxime Proxetil Tablet 200 mg is not a preferred antibiotic for the treatment of staphylococcal pneumonia and should not be used in the treatment of atypical pneumonia caused by organisms such as Legionella, Mycoplasma, and Chlamydia. Cefpodoxime Proxetil Dispersible Tablet 200 mg is not recommended for the treatment of pneumonia due to S. pneumoniae.
As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe hypersensitivity reactions, treatment with cefpodoxime must be discontinued immediately, and adequate emergency measures must be initiated.
Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to Cefpodoxime Proxetil Tablet 200 mg, to other cephalosporins, or to any other type of beta-lactam agent. Caution should be used if cefpodoxime is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.
In cases of severe renal insufficiency, it may be necessary to reduce the dosage regimen dependent on the creatinine clearance.
Antibacterial agent-associated colitis and pseudomembranous colitis have been reported with nearly all antibacterial agents, including cefpodoxime, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea during or subsequent to the administration of cefpodoxime. Discontinuation of therapy with cefpodoxime and the administration of specific treatment for Clostridium difficile should be considered. Medicinal products that inhibit peristalsis should not be given.
Cefpodoxime should always be prescribed with caution in patients with a history of gastrointestinal disease, particularly colitis.
As with all beta-lactam antibiotics, neutropenia and, more rarely, agranulocytosis may develop, particularly during extended treatment. For cases of treatment lasting longer than 10 days, the blood count should be monitored and treatment discontinued if neutropenia is found.
Cephalosporins may be absorbed onto the surface of red cell membranes and react with antibodies directed against the drug. This can produce a positive Coombs test and, very rarely, hemolytic anemia. Cross-reactivity may occur with penicillin for this reaction.
Changes in renal function have been observed with cephalosporin antibiotics, particularly when given concurrently with potentially nephrotoxic drugs such as aminoglycosides and/or potential diuretics. In such cases, renal function should be monitored.
As with other antibiotics, prolonged use of Cefpodoxime Proxetil Tablet 200 mg may result in the overgrowth of non-susceptible organisms (Candida and Clostridium difficile), which may require interruption of treatment.
Route of administration: oral.
Cefpodoxime Proxetil Tablet 200 mg should be taken with food for optimum absorption.
Adults and adolescents with normal renal function:
Upper respiratory tract infections: Acute bacterial sinusitis: 200 mg twice daily; Tonsillitis: 100 mg twice daily.
Lower respiratory tract infections: Acute exacerbation of chronic bronchitis: 200mg twice daily; Bacterial pneumonia: 200mg twice daily
Elderly:
It is not necessary to modify the dose in elderly patients with normal renal function.
Children:
A pediatric formulation of cefpodoxime is available for infants and children.
Gastric pressure, nausea, vomiting, abdominal pain, flatulence, and diarrhea. The possibility of pseudomembranous enterocolitis should be considered if severe or persistent diarrhea occurs during or after treatment. Bloody diarrhea can occur as a symptom of enterocolitis. Loss of appetite.
Store below 30°C temperature and protect from light.
Keep the medicine out of reach of children.
Alu-Alu blister packs.
Cefpodoxime Proxetil Tablets 200 mg are available in an Alu-Alu blister of 10 tablets. Such 01 blister in a mono carton with package insert and such 10 mono cartons in a unit box.
Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.
Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.
A pharma CMO is a special kind of an organization, offering contract manufacturing services to pharmaceutical companies for various kinds of drug formulations.
Reduce overall costs and time to market :
Contract manufacturers already have the needed infrastructure and technical staff, so working with a CMO or CDMO can decrease the cost of manufacturing your pharmaceutical products.
Scalability and flexible production capacity :
You can produce what you need when you need it without worrying about excess capacity. Additionally, CMOs understand the importance of quality and compliance, so you don't have to sacrifice safety for scalability.
Save on upgrading and maintaining equipment :
If you have your manufacturing facility, you’ll have to pay to upgrade your equipment as technology advances—which can get expensive. A CMO/CDMO’s only function is to make and distribute products, so part of their core business responsibility is to update their equipment whenever needed and perform maintenance.
Ease supply chain issues :
During the pandemic, there were several instances of supply chain issues, including medicine shortages. CMOs are generally better equipped than startups to handle a supply chain crisis.
Bandwidth to focus on core competencies
When your company resources aren’t directly allocated to manufacturing and distribution, you have more time to focus on other tasks, like marketing your new drug, researching, or working on drug discovery.
We have 7+ manufacturing sites with a minimum of WHO GMP certification and other country-specific approvals like NAFDAC approved, PPK Kenya Approved, TFDA Tanzania Approved, EU-GMP Approved.
We have below manufacturing capacity:
For Tablet, Capsule, and soft gel: up to 1 million units per shift
For Syrup: up to 0.05 Million per shift
For Ampoule and Vial: up to 0.1 million units per shift
For Ointment and Cream: up to 0.1 million units per shift
For Suppository: 0.1 Million units per shift
